GlassScriptPhysician profile
Juan C Ramirez
NPI 1285654350
$1,750.28
in general payments reported to CMS, 2019-2025
14 companies · $42.69 in 2025
The $42.69 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $448 · 2020: $331 · 2021: $304 · 2022: $354 · 2023: $236 · 2024: $33.55 · 2025: $42.69.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $312.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $385.15 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $178.37 | 2019-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.81 | 2019-2020 | |
| Amarin Pharma, INC. | $151.71 | 2020-2021 | |
| Dexcom, INC. | $143.47 | 2022-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $141.42 | 2019-2021 | |
| Lilly USA, LLC | $127.46 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.64 | 2022-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $98.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $97.31 | 2021-2023 | |
| Endogastric Solutions, INC | $51.19 | 2019 | |
| Merck Sharp & Dohme LLC | $35.12 | 2019 | |
| Horizon Therapeutics Plc | $26.08 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $18.90 | 2024 | Pomalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Juan Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.